StockData
ImmunityBio, Inc. logo

ImmunityBio, Inc. (IBRX) income statement

IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$6.57−0.13 (-1.94%)

Close on Nov 19, 2026Market cap $6.96BP/E –Yield –

See a number that looks wrong?